Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
- PMID: 29298852
- PMCID: PMC5791797
- DOI: 10.1212/WNL.0000000000004888
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Abstract
Objective: To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry.
Methods: Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing.
Results: Serum levels of caffeine and 9 of its downstream metabolites were significantly decreased even in patients with early PD, unrelated to total caffeine intake or disease severity. No significant genetic variations in CYP1A2 or CYP2E1, encoding cytochrome P450 enzymes primarily involved in metabolizing caffeine in humans, were detected compared with controls. Likewise, caffeine concentrations in patients with PD with motor complications were significantly decreased compared with those without motor complications. No associations between disease severity and single nucleotide variants of the ADORA2A gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis.
Conclusion: Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies.
Classification of evidence: This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures

Comment in
-
Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough.Neurology. 2018 Jan 30;90(5):205-206. doi: 10.1212/WNL.0000000000004898. Epub 2018 Jan 3. Neurology. 2018. PMID: 29298853 No abstract available.
References
-
- Postuma RB, Berg D, Stern M, et al. . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1601. - PubMed
-
- Ascherio A, Zhang SM, Hernan MA, et al. . Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56–63. - PubMed
-
- Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276–284. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials